This is the case of trastuzumab, approved for the treatment of human epidermal growth factor receptor-2 (HER-2) positive breast and gastric tumors [16], and that it is present in two approved ADCs: Kadcyla® and Enhertu®. This evidence concerns the gene ERBB2 and gastric neoplasm.